TOBI (tobramycin)
TOBI is an aminoglycoside antibacterial indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with *Pseudomonas aeruginosa*. Safety and efficacy have not been demonstrated in patients under 6 years of age, patients with a forced expiratory volume in 1 second (FEV1) <25% or >75% predicted, or patients colonized with *Burkholderia cepacia*.
How TOBI Works
Tobramycin is an aminoglycoside that acts primarily by binding irreversibly to the 30S ribosomal subunit of susceptible bacteria. This binding interferes with the initiation complex of protein synthesis and induces misreading of the mRNA template, leading to the production of nonfunctional proteins and eventual bacterial cell death. In cystic fibrosis, the inhaled formulation provides high concentrations of the drug directly to the airways to combat *Pseudomonas aeruginosa* biofilms.
Details
- Status
- Prescription
- First Approved
- 1997-12-22
- Routes
- INHALATION
- Dosage Forms
- SOLUTION
TOBI Approval History
What TOBI Treats
1 indicationsTOBI is approved for 1 conditions since its original approval in 1997. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Cystic Fibrosis
TOBI Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to TOBI
3 of 12FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
17 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02918409 results posted | SAAVED15A0 | Ph 4 | completed | IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy |
| NCT04872400 APOW results posted | 20-2957 5672 | Ph 4 | completed | Acute Application of Antibiotic Powder in Open Fracture Wounds |
| NCT05429671 | MAUS21D.1213 | Ph 3 | completed | Antibiotic Loaded Cement After TKA |
| NCT03705962 results posted | 18088 | Ph 3 | terminated | Locally Applied Antibiotics for Infection Prophylaxis in Treatment of Open Fractures |
| NCT02873806 | GCF-039 | Ph 4 | completed | Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents |
| NCT03673956 results posted | 18-006599 | Ph 1, Ph 2 | completed | Topical Antibiotics in Chronic Rhinosinusitis |
| NCT03904836 ESRD | 2019-1619 | Ph 1 | completed | Tobramycin Administered at the Beginning of Dialysis |
| NCT02212587 results posted | TIPBCC002 165476 | Ph 1 | completed | Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex |
| NCT01111383 CT03Ext | CMA-0631-PR-0010 Extension | Ph 3 | completed | A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI® |
| NCT02207426 | TobrAir - CT0040 2013-005288-19 | Ph 1 | completed | Pharmacokinetic and Pharmacoscintigraphic Comparison of TobrAir® 6.0 With TOBI® and TOBI® Podhaler™ |
| NCT00634192 | CTBM100DDE01 | Ph 3 | completed | Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin |
| NCT01082367 EARLY results posted | CTBM100C2304 2009-016590-15 | Ph 3 | completed | Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years |
| NCT02269969 | 183-2014 | Ph 1, Ph 2 | completed | Once Daily Aminoglycoside Pharmacokinetics and Optimal Dosing in the Burn Population: A Prospective Study |
| NCT00705159 results posted | 550 | Ph 4 | completed | Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis |
| NCT02035488 | Tobra-02 | Ph 1, Ph 2 | completed | Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis |
| NCT01155999 results posted | LT1225-PIIIB-02/08 2008-003567-39 | Ph 3 | completed | Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children. |
| NCT01608555 | SP2 2011-001821-26 | Ph 4 | completed | Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TOBI FDA Label Details
Indications & Usage
FDA Label (PDF)TOBI is indicated for the treatment of Cystic Fibrosis.
Track TOBI with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.